Scientists synthesize terpenoids with microbial consortium

According to a study published in Microbial Cell Factories, a team led by Prof. Zheng Zhiming and associate Prof. Wang Peng from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences has enhanced the synthesis ability of terpenoids with newly developed microbial consortia.

The research team used Escherichia coli as the precursor substrate donor to designed and optimized the consortium of Elizabethkingia meningoseptica and E. coli so as to achieve their goal.

“The E. meningoseptica and E. coli co-culture strategy can improve vitamin K2 biosynthesis,” said Prof. Wang Peng.

Application of microbial consortia is a hot spot in the field of metabolic engineering and synthetic biology. As a kind of terpenoid, vitamin K2 has important physiological functions such as preventing osteoporosis and promoting blood coagulation. E. meningoseptica is an important strain for synthesizing vitamin K2 with different lengths of side chains, but this strain lacks molecular manipulation and is difficult to carry out directional transformation.

By introducing the mevalonate pathway and isopentenyltransferase genes from E. meningoseptica into E. coli, the team constructed a microbial consortium of E. meningoseptica and E. coli, which was approximately threefold that of the titer achieved with E. meningoseptica sp. F2 monoculture.

Further studies showed that there was a close relationship between the cocultured strains, which improved the lipase activity and membrane permeability, and realized the material exchange between bacteria.

This study lays the foundation for the further application of E. meningoseptica and E. coli consortia for the biosynthesis of MK-n (n=4, 5, 6, 7, 8) and other terpenoids.